TickerFacts.

Biogen Inc. (BIIB): Cost of Revenue

Annual figures by period end, from SEC filings.

$2.40B
Year ended 2025-12-31
$2.44B
Trailing 12 months to 2026-03-31
+1.8%
3-year compound annual growth
+5.9%
5-year compound annual growth
+6.8%
10-year compound annual growth
$2.53B2007-12-31: $335.19M2008-12-31: $401.99M2009-12-31: $382.10M2010-12-31: $400.26M2011-12-31: $466.78M2012-12-31: $545.49M2013-12-31: $857.70M2014-12-31: $1.17B2015-12-31: $1.24B2016-12-31: $1.48B2017-12-31: $1.63B2018-12-31: $1.82B2019-12-31: $1.96B2020-12-31: $1.81B2021-12-31: $2.11B2022-12-31: $2.28B2023-12-31: $2.53B2024-12-31: $2.31B2025-12-31: $2.40B$2.40B
2007-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$2.40B+4.1%2026-02-06, From 2025-01-01
2024-12-31$2.31B-8.8%2026-02-06, From 2024-01-01
2023-12-31$2.53B+11.2%2026-02-06, From 2023-01-01
2022-12-31$2.28B+8.0%2025-02-12, From 2022-01-01
2021-12-31$2.11B+16.9%2024-02-14, From 2021-01-01
2020-12-31$1.81B-7.7%2023-02-15, From 2020-01-01
2019-12-31$1.96B+7.7%2022-02-03, From 2019-01-01
2018-12-31$1.82B+11.4%2021-02-03, From 2018-01-01
2017-12-31$1.63B+10.2%2020-02-06, From 2017-01-01
2016-12-31$1.48B+19.2%2019-02-06, From 2016-01-01
2015-12-31$1.24B+5.9%2018-02-01, From 2015-01-01
2014-12-31$1.17B+36.5%2017-02-02, From 2014-01-01
2013-12-31$857.70M+57.2%2016-02-03, From 2013-01-01
2012-12-31$545.49M+16.9%2015-02-04, From 2012-01-01
2011-12-31$466.78M+16.6%2014-02-06, From 2011-01-01
2010-12-31$400.26M+4.8%2013-02-05, From 2010-01-01
2009-12-31$382.10M-4.9%2012-02-03, From 2009-01-01
2008-12-31$401.99M+19.9%2011-02-04, From 2008-01-01
2007-12-31$335.19Mn/a2010-02-09, From 2007-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Biogen Inc. (BIIB)2025-12-31$2.40B+4.1%
Gilead Sciences, Inc. (GILD)2025-12-31$6.23B-0.3%
Neurocrine Biosciences Inc (NBIX)2025-12-31$52.10M+53.2%
Amgen Inc (AMGN)2025-12-31$12.04B-6.4%
Exelixis, Inc. (EXEL)2026-01-02$83.70M+9.8%
Qiagen N.V. (QGEN)2025-12-31$790.50M-21.8%
Moderna, Inc. (MRNA)2025-12-31$868.00M-40.7%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$228.77M+43.5%
Bio-Techne Corp (TECH)2026-06-30$415.97M-3.1%

Compare BIIB, GILD, NBIX, AMGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗